LOI and Term Sheet Red Flags in Healthcare Deals
A healthcare LOI is mostly nonbinding. Its exclusivity clause does bind you, and its terms become the first draft of the purchase agreement. The red flags that cost sellers the most sit in eight places: a price tied to "EBITDA as determined in diligence," an undefined working capital peg, a loose list of debt-like items, an earnout the buyer measures, rollover equity priced above the sponsor's, an escrow above market with no insurance, open-ended exclusivity, and closing conditions that give the buyer a free option to walk. The 26 items below show each red flag, what it costs and what to ask for. A scoring screen at the end shows which gaps to close before you sign.
Data as of November 20, 2026. Deal-term figures come from SRS Acquiom's 2026 escrow and earnout studies (2025 private-target deals, all sectors unless labeled). Deal counts come from the Private Equity Stakeholder Project's 2025 review (PitchBook and LevinPro HC data) and Bain & Company's Global Healthcare Private Equity Report 2026. Spending data comes from CMS.
Why the buyer's template sets the terms
Buyers are paying for a growing revenue pool. Per the CMS National Health Expenditure fact sheet, physician and clinical services spending topped $1 trillion in 2024, and CMS projects continued growth through 2034.
Most practice sellers will get their LOI from a platform. The Private Equity Stakeholder Project tracked 1,029 PE-backed U.S. healthcare deals in 2025, and 664 of them were add-on acquisitions. In dental, 95% of the 149 deals PESP tracked were add-ons by PE-owned platforms, and ten of the 18 most active platforms were dental companies. The outpatient figures are PESP data as reported by Becker's ASC Review, not taken from the PESP review directly. They show 148 outpatient deals in 2025, 119 of them add-ons, led by dermatology (24) and eye care (22). PESP says its counts are likely an underestimate.
An add-on LOI comes off a template the buyer has used dozens of times, so every default favors the buyer. The 26 items below are where those defaults sit.
Price mechanics: 7 clauses that decide cash at close
The headline number is enterprise value. What reaches your account is that number minus debt, debt-like items, any working capital shortfall, escrow and every deferred piece. Expect the peg to move money. Of the 2025 deals in SRS Acquiom's 2026 Deal Terms for M&A Escrows, 93% had a purchase price adjustment (PPA) mechanism, and most of those saw the price actually adjusted after closing.
Two different things move price after signing:
- A PPA is contractual. It trues up working capital, debt and cash against the definitions in the purchase agreement. Items 2 to 4 limit it.
- A re-trade is a renegotiation. The buyer's quality of earnings (QoE) report comes back showing lower EBITDA, and the nonbinding price changes. Items 1 and 23 limit it.
| # | Clause | Red flag | Why it costs you | What to ask for |
|---|---|---|---|---|
| 1 | Valuation basis | Price stated as a multiple of "EBITDA as determined in diligence" | The buyer's QoE resets the base after you have granted exclusivity | A fixed dollar price, or a stated EBITDA figure plus the list of accepted addbacks |
| 2 | Cash-free, debt-free | "Indebtedness" left undefined, or defined to include patient credit balances, deferred revenue, accrued bonuses or payor recoupment reserves | Every debt-like item cuts the price dollar for dollar | A named list of debt-like items in the LOI itself |
| 3 | Working capital peg | Peg "to be agreed," or set from a single month-end | A high peg turns into a price cut at closing | A peg based on the trailing 12-month average of normalized net working capital, with the method attached |
| 4 | Accounts receivable | AR valued at gross charges, or with no payor-level reserve method | Healthcare AR is overstated at gross, so the true-up lands on you | AR at historical net collection rates by payor class, with the same method before and after closing |
| 5 | Cash at close | Less than half of the headline price paid at closing | Deferred value carries buyer, lender and performance risk | Cash at close stated as a dollar figure and as a percent of the headline price |
| 6 | Seller note | Unsecured, subordinated to the senior lender, PIK interest or a balloon payment | You become a junior creditor of a debt-funded company | Security, current-pay interest, amortization, and acceleration on default or resale |
| 7 | Transaction expenses | Buyer's RWI premium, QoE cost or lender fees charged to the seller | Moves buyer costs into your price | An expense split written into the LOI |
Worked example 1, the peg (hypothetical, our arithmetic). A dermatology practice signs at $24.0 million. The LOI sets the peg at $1.4 million, taken from the December balance. Normalized trailing 12-month working capital is $1.1 million. If you deliver $1.1 million at closing against a $1.4 million peg, the price drops by $300,000 ($1.4 million minus $1.1 million) before any escrow comes out. Run your own waterfall in the deal proceeds calculator, and build support for the peg with the QoE prep checklist.
Worked example 2, the seller note (hypothetical, our arithmetic). The same practice takes $2.0 million of the price as a five-year subordinated note with 8% PIK interest and a balloon at maturity. Compounded annually, the balance at maturity is about $2.94 million ($2.0 million x 1.08^5). You receive no cash for five years, and the whole balance sits behind the senior lender. A current-pay note on the same $2.0 million at 8% pays $160,000 a year in cash from year one.
Earnouts and rollover equity: 6 definitions that move the payout
Earnouts are now standard in healthcare services. The SRS Acquiom 2026 M&A Earnout and Milestone Trends report has these figures:
| Population (SRS Acquiom private-target deals) | 2025 earnout rate | 2014 to 2022 earnout rate |
|---|---|---|
| Healthcare services targets | 37% | 26% |
| U.S. private equity buyers | 24% | 13% |
| All deals excluding life sciences | 24% | Not reported |
| Deals valued at $50M or less | 30% | 23% |
| Deals valued above $750M | 6% | 5% |
Payouts trail the headline. In the same study, lower middle-market deals with any earnout achievement paid a median of 43 cents on the dollar. Confirm the report's size cutoff and sample size for that group before you apply the figure to your deal. Deals with upfront payments above $50 million and any earnout success paid a median of 67 cents. That larger-deal figure does not fit the $20 million to $30 million examples on this page, so the worked examples use the 43-cent median as the closer fit. That fit is an assumption, not a tested match to $20 million to $30 million deals. Both medians count only earnouts that paid something. Earnouts that paid nothing are left out, so the expected value across all earnouts is lower. Price that in, as worked example 3 does.
| # | Clause | Red flag | Why it costs you | What to ask for |
|---|---|---|---|---|
| 8 | Earnout metric | EBITDA "as calculated by Buyer," with corporate overhead or MSO fees allocated after closing | The buyer controls the inputs to the metric | GAAP on the same basis as the QoE, overhead excluded, and a sample calculation as an exhibit |
| 9 | Operating covenants | Buyer free to move providers, close sites or renegotiate payor contracts | You carry the target while the buyer controls the inputs | Covenants to run the business consistently, plus acceleration on resale or termination without cause |
| 10 | Referral-linked payments | Earnout, seller note or rollover paid to selling physicians who will keep referring to the buyer, with a metric tied to revenue they generate or order | Payments linked to referrals draw regulatory scrutiny, and a bad structure can put the whole deal at risk | A metric and payment design reviewed by your healthcare regulatory counsel before you sign |
| 11 | Set-off | Buyer may offset any claimed indemnity against the earnout | An unresolved claim freezes your payout | Set-off only for claims that are finally determined |
| 12 | Rollover price | Rolled equity priced above the cash valuation, or issued in a junior class | Your rolled dollars buy less than the sponsor's | Same price per unit and same class as the sponsor's equity |
| 13 | Rollover rights | No tag-along, no information rights, call at the lower of cost or FMV on any departure | The buyer controls your liquidity and your exit value | Tag-along, drag only at the same price, FMV call except for cause, quarterly financials, and the issuing entity named |
When you roll equity, the buyer is your partner through the next exit, and that exit is most often another sponsor. Bain's Global Healthcare Private Equity Report 2026 press release expected more than 150 sponsor-to-sponsor healthcare deals in 2025, worth more than $120 billion in estimated value. It also reports that more than 70% of large North American healthcare PE deals in 2025 were sponsor-to-sponsor sales. Items 12 and 13 decide what your rolled equity is worth in that sale.
Check the sponsor before you price its paper. Search the fund name on SEC EDGAR full-text search for Form D notices, which show when and how much private capital it has raised. Then use the reverse due diligence guide and the physician rollover equity checklist. Discount the earnout in the earnout value calculator before you compare it with a cleaner offer.
Worked example 3, two LOIs side by side (hypothetical, our arithmetic). An orthopedic group receives two offers. The "escrow held" line below is the general indemnity escrow only, taken as a percent of the headline price. Median total escrow, which includes any separate PPA escrow, is higher (11.1% without RWI and 2.8% with RWI). The SRS Acquiom medians are cross-sector benchmarks, not healthcare-specific norms.
- LOI A has no RWI. Its escrow is 10.0%, the SRS Acquiom 2025 median general indemnity escrow for deals without RWI.
- LOI B has RWI. Its escrow is 0.5%, the median for deals with RWI.
- Rollover is held at face value in both, since both roll 20%.
- The RWI premium is left out.
- LOI A sets its peg from a single month-end, which produces a $0.4M shortfall at closing. LOI B sets its peg from the trailing 12-month average, which matches the working capital delivered, so it has no shortfall (our assumption).
| Closing line | LOI A | LOI B |
|---|---|---|
| Headline price | $30.0M | $27.0M |
| Cash portion of price | 60%, $18.0M | 80%, $21.6M |
| Rollover equity | 20%, $6.0M | 20%, $5.4M |
| Earnout (face) | 20%, $6.0M | None |
| Less peg shortfall | ($0.4M) | None |
| Less escrow held | 10.0%, ($3.0M) | 0.5%, ($0.135M) |
| Cash delivered at closing | $14.6M | $21.465M |
There are three ways to value the deferred pieces. All three include cash at closing and rollover at face.
| Scenario | LOI A | LOI B | B minus A |
|---|---|---|---|
| Face: escrow released in full, earnout paid in full | $29.6M | $27.0M | ($2.6M) |
| Median: escrow released in full, earnout at 43 cents | $26.18M | $27.0M | $0.82M |
| Probability-weighted: claim risk on escrow, 40% chance the earnout pays nothing | $24.728M | $26.978M | $2.25M |
The probability-weighted row works like this:
- Escrow. SRS Acquiom's 2026 escrow study found indemnification claims (excluding PPAs) on 28% of all deals and on 33% of RWI deals. We apply 28% to LOI A and 33% to LOI B. We assume a claim consumes half the escrow (our assumption). Applying the 33% rate to B's escrow is conservative, since on RWI deals most claims are paid by the policy rather than the escrow. B's true expected release is likely higher, which would widen its lead slightly. Expected release on A is $3.0M x (1 minus 0.28 x 0.5), or $2.58M. On B it is $0.135M x (1 minus 0.33 x 0.5), or about $0.113M.
- Earnout. We assume a 40% chance the earnout pays nothing (our assumption, since the SRS medians leave out zero payouts). We apply the 43-cent median to the other 60%. That gives $6.0M x 0.60 x 0.43, or $1.548M.
- Totals. LOI A is $14.6M + $2.58M + $6.0M + $1.548M = $24.728M. LOI B is $21.465M + $0.113M + $5.4M = $26.978M.
LOI A leads by $3.0 million on the headline. LOI B delivers $6.865 million more at closing and about $2.25 million more on a probability-weighted basis, before the RWI premium split. The result depends on the two assumptions, so change them to fit your deal. On these figures, LOI A pulls ahead once the earnout's expected value passes about 57 cents on the dollar if the escrow is released in full, or about 63 cents after expected escrow claims. Both break-even points sit above the 43-cent median used here, so on these assumptions LOI B ranks ahead unless you expect the earnout to pay well above the typical smaller-deal outcome. Treat the ranking as scenario analysis, not an estimate from deal data, and test a range of probabilities before you rely on it.
Escrow, RWI and indemnity: 5 terms to price against market data
Whether the deal carries reps and warranties insurance is the biggest driver of escrow size. The figures below come from SRS Acquiom's 2026 Deal Terms for M&A Escrows. They cover 2025 private-target deals across sectors, not healthcare alone.
| SRS Acquiom 2025 deals, % of transaction value | With RWI, average | With RWI, median | Without RWI, average | Without RWI, median |
|---|---|---|---|---|
| Total escrow | 5.1% | 2.8% | 14.7% | 11.1% |
| General indemnity escrow | 2.2% | 0.5% | 11.3% | 10.0% |
Insurance does not remove the holdback. In the same study, most deals with RWI still had an indemnification escrow or holdback, as did most deals without it. Claims are common, with 28% of all deals and 33% of RWI deals seeing indemnification claims outside PPAs.
| # | Clause | Red flag | Why it costs you | What to ask for |
|---|---|---|---|---|
| 14 | Escrow size | Above the 2025 medians with no specific diligence finding behind it | Your money sits idle as the buyer's insurance | Size matched to the data, with any excess tied to a named issue |
| 15 | Release schedule | One release at the end of the longest survival period | Holds all of your cash for the longest exposure | Staged releases, with a separate PPA escrow released after the true-up |
| 16 | RWI allocation | LOI silent on RWI, or the seller pays the premium and the full retention | Without RWI you face the larger escrow. With a bad split you pay for the buyer's policy | Who pays the premium, how the retention is split, and seller exposure capped at a share of the retention |
| 17 | Cap and survival | General reps capped at the full price, or survival left open | Turns a sale into an open-ended liability | General reps capped at the escrow, a fixed survival period, and a short, named list of fundamental reps |
| 18 | Special indemnity | Uncapped indemnity for "all pre-closing billing and coding" | RWI policies generally exclude known issues, so this lands on you | Defined scope, a cap, a time limit, and a tie to a specific diligence finding |
Survival is negotiable even with insurance. In SRS Acquiom's 2025 data, 43% of RWI deals let the seller's general reps and warranties survive closing. The other 57% were no-survival deals, where the buyer looks to the policy for general rep breaches. If your deal carries RWI, ask for no survival on general reps and point to that 57%.
Worked example 4, escrow (hypothetical, our arithmetic). On a $20 million sale without RWI, the 10.0% median general indemnity escrow holds $2.0 million. With RWI and the 0.5% median, it holds $100,000. On total escrow the gap is $2.22 million (11.1%) against $560,000 (2.8%). RWI frees about $1.66 million of closing cash, before the premium.
Structure, employment, non-competes, exclusivity and closing: items 19 to 26
These items sit where business terms meet healthcare regulation. The LOI does not need to settle the law. It needs to state the structure, the pay and the timeline in enough detail to be tested before exclusivity starts.
| # | Clause | Red flag | Why it costs you | What to ask for |
|---|---|---|---|---|
| 19 | Deal structure (practice entity and MSO) | LOI assumes the buyer owns the professional entity outright, or describes an MSO model with no detail on who owns the practice entity or how the management fee is set | A structure that does not fit the ownership rules where you practice forces a late restructuring, a delay or a re-trade | A one-page structure chart in the LOI showing who owns the practice entity, what the MSO buys, and the basis of the management fee |
| 20 | Employment compensation | "Consistent with Buyer's model" with no numbers, or a wRVU rate below today's | A post-close pay cut funds part of the buyer's return | Base pay, wRVU rate, term and fair market value support stated in the LOI |
| 21 | Termination | Termination without cause triggers forfeiture of rollover or earnout | The buyer can buy back your upside cheaply | Good-leaver treatment on termination without cause, death or disability |
| 22 | Non-compete | Radius, specialty and duration undefined, or the clock starts when employment ends | Can stretch well past the sale | Separate sale and employment covenants, a defined radius per site, and fall-away on termination without cause |
| 23 | Exclusivity | Open-ended, auto-renewing, or still in force after a price cut | Holds you while the buyer re-trades | A fixed term that ends automatically if the buyer reprices |
| 24 | Closing conditions | Financing contingency, "satisfactory diligence," or investment committee approval | Gives the buyer a free option to walk | Committed financing and confirmatory diligence only |
| 25 | Regulatory filings | Silent on federal and state notice filings and fees, or an outside date too short for the reviews that apply | The deal stalls or lapses before closing | Who files, who pays, and an outside date that covers every notice and review that applies |
| 26 | Binding terms | Seller expense reimbursement or a break fee made binding | Penalizes you for walking away from a re-trade | Only exclusivity, confidentiality and governing law binding |
Who settles each open item before you grant exclusivity
Most LOI gaps stay open because no one owns them. Give each group of items a named owner and a written output before the exclusivity clause takes effect.
| Items | Owner on your side | Written output before exclusivity |
|---|---|---|
| 1, 3, 4 (valuation basis, peg, AR) | Finance lead and your QoE provider | Stated EBITDA with accepted addbacks, trailing 12-month peg support, AR at net collection rates by payor class |
| 2, 5, 6, 7 (debt-like items, cash at close, seller note, expenses) | Banker or finance lead | Named debt-like list, cash at close in dollars and percent, note terms, expense split |
| 8, 9, 11 (earnout metric, covenants, set-off) | Finance lead, with the buyer's deal team | Sample earnout calculation on your last 12 months, operating covenant list |
| 10, 19, 20, 22 (referral-linked pay, structure, compensation, non-compete) | Your healthcare attorney | Written comments on the structure chart, pay terms and covenants |
| 12, 13, 21 (rollover price, rights, termination) | Attorney and CPA | Marked-up rollover term summary and tax summary |
| 14 to 18 (escrow, release, RWI, caps, special indemnity) | Attorney and banker | Escrow size against the SRS Acquiom medians, RWI cost split, cap and survival terms |
| 23, 24, 26 (exclusivity, closing conditions, binding terms) | Banker | Fixed exclusivity term with a reprice exit, closing conditions limited to confirmatory diligence |
| 25 (regulatory filings) | Attorney | Filing list, fee split and an outside date that fits the timeline |
High-risk area: referral-linked pay, practice structure and regulatory filings (items 10, 19, 20 and 25). These terms can decide whether the deal can close, how it has to be structured and how long it takes. Why ask before signing: once exclusivity starts, a structure or pay problem found late usually means a restructuring, a delay or a price cut, and by then your other bidders are gone. The risks reach past the deal itself. Pay tied to referrals can expose the buyer and the selling physicians to regulatory penalties. A structure that does not fit local ownership rules can force an unwind. Missed notice filings can push closing past the outside date. Rules in this area differ by state and change over time, so do not rely on this page, another website or an AI tool for an answer on your deal. Ask your own healthcare attorney these questions before you sign:
- Does any earnout, seller note, rollover or pay term rise or fall with referrals, or with services the selling physicians will order after closing? If so, how should the metric be redesigned?
- Does the proposed ownership of the practice entity, and the MSO arrangement, fit the rules where we practice? Is the management fee supportable as fair market value?
- Is post-closing compensation backed by an independent fair market value review, and who pays for it?
- Which government notices or reviews could apply to this deal? Who files them, and is the outside date long enough to cover them?
- Could a success fee paid to any intermediary raise its own regulatory questions?
Background is in the healthcare compliance due diligence guide, the healthcare M&A process guide and the guide to choosing a healthcare investment banker.
Pre-signing packet: 9 documents to send with the draft LOI
Items 10 and 19 to 25 can only be tested against facts on paper. Send this packet with the draft LOI so the review happens before exclusivity, not during it.
| # | Document | Where it comes from | Items it tests |
|---|---|---|---|
| 1 | Draft LOI with each of the 26 items marked as stated, missing or flagged | Your redline | All |
| 2 | Current ownership chart of the practice entity and any existing management company | Corporate records | 19 |
| 3 | List of selling physicians who will keep treating and ordering after closing, with planned roles | Practice leadership | 10, 20, 21 |
| 4 | Current pay plans, wRVU rates and productivity reports for each provider | Payroll and practice management system | 20 |
| 5 | Existing employment, partnership and non-compete agreements | Corporate records | 21, 22 |
| 6 | The buyer's earnout definition, with a sample calculation run on your last 12 months | QoE workpapers | 8, 10, 11 |
| 7 | Rollover term summary: issuing entity, unit class, price per unit, tag, drag and call terms | Buyer | 12, 13 |
| 8 | Revenue by site, states of operation, and the buyer's other holdings in your market | Finance team and buyer | 25 |
| 9 | Tax summary of cash, rollover, earnout and seller note | Your CPA | 5, 6, 12 |
The healthcare compliance due diligence guide, the management services organizations guide and the physician investors guide cover the background on referral-linked pay, practice ownership and physician-held rollover.
Scoring rule: 26 points before you sign
Give one point for each item where the LOI states the term in numbers or defined words and none of the red flags apply. The score is a screen, and its cutoffs are our editorial heuristic, not a validated standard. It does not replace deal-specific judgment from your attorney and banker on the terms that carry the most money.
Five items are gating: 1 (valuation basis), 5 (cash at close), 10 (referral-linked payments), 23 (exclusivity) and 24 (closing conditions). A red flag on any of them blocks signing whatever the total. Each one either hands the buyer a free option or puts the deal at regulatory risk.
| Score | Read | Action |
|---|---|---|
| 23 to 26, no gating flags | Clean on this screen | Have your advisors confirm the high-dollar terms, then move toward signing |
| 16 to 22, no gating flags | Workable with gaps | Close the gaps that carry the most dollars before exclusivity starts |
| Below 16, or any gating flag | Buyer keeps the option | Hold off on exclusivity and run the other bidders |
Fix gaps in dollar order. On a $10 million deal, a missing expense split (item 7) costs less than an undefined peg (item 3) or a 10% escrow without RWI (item 14).
How to run the LOI round
| Practice | Why it works |
|---|---|
| Send every bidder the same LOI grid: price, cash at close, peg method, debt-like list, earnout definition, rollover terms, escrow, RWI, structure chart and exclusivity term | Each buyer has to answer items 1 to 26 in numbers, so offers compare like for like |
| Set the peg method and the debt-like list before LOIs arrive | Buyers price against your numbers instead of their own |
| Ask each bidder for two references from sellers who rolled equity with it, including one whose earnout missed | Shows how the buyer behaves when the plan goes wrong |
| Convert every LOI to the three scenarios in worked example 3 | Stops a large earnout from winning on headline price alone |
| Keep a second bidder engaged until exclusivity terms are final | Your bargaining power on items 1, 23 and 24 depends on having an alternative |
| Before granting exclusivity, close the gating items and the highest-dollar gaps the screen surfaces | Every open point gets harder to win once the buyer has the exclusive |
Investors backing a platform can use the same 26 items from the other side. A seller who pushes back on none of them often re-trades or walks later, once their advisors read the purchase agreement.
30/60/90-day order of work around the LOI
See the healthcare M&A timeline chart.
| Window | Work | Output |
|---|---|---|
| Days 1 to 30 (before LOIs) | Normalize 12 months of working capital, list debt-like items, model AR at net collection rates, map the practice ownership structure, identify federal and state notice triggers | Peg support, debt-like list, structure chart, regulatory timeline |
| Days 31 to 60 (LOI round) | Convert each LOI to cash at close plus probability-weighted deferred value, redline items 1 to 26, vet bidders on EDGAR and through seller references | One comparison table, and a signed LOI with no gating flags and its high-dollar gaps closed |
| Days 61 to 90 (exclusivity) | RWI underwriting, fair market value support for employment terms, regulatory filings, disclosure schedules, earnout exhibit | A draft purchase agreement that matches the LOI with no re-trade |
Questions owners ask
Is a healthcare LOI legally binding?
Price and structure are usually written as nonbinding. Exclusivity, confidentiality and governing law are usually binding, and some LOIs also make expense reimbursement binding. The nonbinding terms still matter because the LOI becomes the first draft of the purchase agreement. Any point you leave open gets settled during exclusivity, when you have less room to push back.
How big should the escrow be in a healthcare sale?
It depends on whether the deal uses reps and warranties insurance (RWI). SRS Acquiom's 2026 escrow study covers 2025 private-target deals across all sectors. It puts total escrow at a median of 2.8% of transaction value on deals with RWI and 11.1% on deals without it. If an LOI asks for more than those medians with no specific diligence finding behind it, ask the buyer to explain the gap or to price in RWI.
How much of an earnout actually gets paid?
Less than the headline. SRS Acquiom's 2026 earnout study found that lower middle-market deals with any earnout achievement paid a median of 43 cents on the dollar. Deals with upfront payments above $50 million and any earnout success paid 67 cents. Both medians count only earnouts that paid something, so the expected value across all earnouts is lower. Model a zero-payout case, compare LOIs on cash at close, and push for definitions you can measure from your own books.
Should I take the LOI with the highest price?
Only after converting each LOI to cash at close plus probability-weighted deferred value. A higher headline price with a large earnout, a big escrow and a high working capital peg can deliver less than a lower, cleaner offer. In worked example 3, under stated assumptions about claims and a zero-payout earnout case, a $30.0 million LOI is worth about $2.25 million less than a $27.0 million LOI. Treat that as scenario analysis, not a forecast. If you roll equity, the buyer's record in your specialty and its exit history count as much as the multiple.
Sources
- SRS Acquiom, 2026 Deal Terms for M&A Escrows, 2025 deal data
- SRS Acquiom, 2026 M&A Earnout and Milestone Trends, 2025 deal data
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review (PitchBook and LevinPro HC data)
- Becker's ASC Review, The outpatient specialties that dominated 2025 deal activity (PESP data)
- Bain & Company, Global Healthcare Private Equity Report 2026 press release
- Centers for Medicare & Medicaid Services, National Health Expenditure fact sheet, 2024 data, accessed November 2026
- U.S. Securities and Exchange Commission, EDGAR full-text search, accessed November 2026